Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMCL2OK)

Drug Name
Disulfiram Drug Info
Synonyms
Abstenisil; Abstinil; Abstinyl; Alcophobin; Antabus; Antabuse; Antadix; Antaenyl; Antaethan; Antaethyl; Antaetil; Antalcol; Antetan; Antethyl; Antetil; Anteyl; Anthethyl; Antiaethan; Anticol; Antietanol; Antiethanol; Antietil; Antikol; Antivitium; Aversan; Averzan; Bonibal; Contralin; Contrapot; Cronetal; Dicupral; Disetil; Disulfan; Disulfirame; Disulfiramo; Disulfiramum; Disulfirm; Disulfram; Disulfuram; Disulphuram; Ephorran; Espenal; Esperal; Etabus; Ethyldithiourame; Ethyldithiurame; Exhoran; Exhorran; Gababentin; Hoca; Krotenal; Nocbin; Nocceler; Noxal; Refusal; Stopaethyl; Stopethyl; Stopety; Stopetyl; TATD; TETD; THIOCID; TTD; TTS; Tenurid; Tenutex; Tetidis; Tetradin; Tetradine; Tetraethylthiuram; Tetraetil; Teturam; Teturamin; Thireranide; Thiuranide; Tillram; Tiuram; Accel TET; Akrochem TETD; Ancazide ET; Antab use; Disulfirame [DCIT]; Ekagom DTET; Ekagom TEDS; Ekagom TETDS; Ekaland TETD; Esperal [France]; Eta bus; Ethyl Thiram; Ethyl Thiudad; Ethyl Thiurad; Ethyl Tuads Rodform; Ethyl Tuex; Ethyl tuads; Etyl Tuex; Nocceler TET; Perkacit TETD; Perkait TETD; Robac TET; Sanceler TET; Soxinol TET; TTS x; Tet raethylthiuram; Thiuram E; Dupon 4472; T 1132; Accel TET-R; Alk-aubs; Antabus (TN); Antabuse (TN); Anti-ethyl; Antivitium (Spain); ENT 27,340; Nocceler TET-G; Noxal (VAN); Ro-sulfiram; Sanceler TET-G; Tuads, ethyl; Usaf B-33; Ro-Sulfram-500 (USA)
Therapeutic ClassAlcohol Deterrents
Cross-matching ID
PubChem CID
3117
ChEBI ID
CHEMBL964
CAS Number
CAS 97-77-8
TTD Drug ID
D0X5SD
VARIDT Drug ID
DR00310
INTEDE Drug ID
DR0519
ACDINA Drug ID
D00206

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
IL-17 signaling pathway 2.48 0.00e+0 84/94 (89.36%) FOSL1;MMP1;CXCL8;...
Rheumatoid arthritis 2.28 0.00e+0 78/93 (83.87%) MMP1;CXCL8;CXCL2;...
NF-kappa B signaling pathway 2.23 0.00e+0 90/104 (86.54%) GADD45B;CXCL8;CD40;...
Toxoplasmosis 2.18 0.00e+0 103/112 (91.96%) HSPA1A;HSPA6;CD40;...
TNF signaling pathway 2.09 2.13e-3 103/112 (91.96%) CXCL2;CEBPB;LIF;...
Legionellosis 2.09 1.78e-3 51/57 (89.47%) HSPA1A;HSPA6;CXCL8;...
Protein processing in endoplasmic reticulum 2.09 1.52e-3 127/171 (74.27%) HSPA1A;HSPA6;PPP1R15A;...
Pertussis 2.05 1.33e-3 64/76 (84.21%) CXCL8;FOS;C1QA;...
Proteasome 2.02 1.18e-3 44/46 (95.65%) PSMD12;ADRM1;PSMD3;...
Epithelial cell signaling in Helicobacter pylori infect... 2.00 1.07e-3 62/70 (88.57%) CXCL8;CXCL2;HBEGF;...
Tuberculosis 1.97 9.68e-4 159/180 (88.33%) CEBPB;HLA-DQA1;IL18;...
Mineral absorption 1.96 8.88e-4 48/60 (80%) HMOX1;MT1X;MT1E;...
Lipid and atherosclerosis 1.95 8.19e-4 190/215 (88.37%) HSPA1A;HSPA6;MMP1;...
Cytosolic DNA-sensing pathway 1.89 7.61e-4 52/63 (82.54%) IL18;AIM2;CXCL10;...
Colorectal cancer 1.88 7.10e-4 84/86 (97.67%) GADD45B;CDKN1A;FOS;...
Osteoclast differentiation 1.88 6.66e-4 117/127 (92.13%) FOSL1;FOSB;SQSTM1;...
Malaria 1.88 6.27e-4 44/50 (88%) CXCL8;CD40;IL18;...
Toll-like receptor signaling pathway 1.83 2.37e-3 94/104 (90.38%) CXCL8;CD40;CXCL9;...
Systemic lupus erythematosus 1.83 2.80e-3 45/135 (33.33%) CD40;HLA-DQA1;C1QA;...
Spliceosome 1.82 3.73e-3 101/150 (67.33%) HSPA1A;HSPA6;SNRPB;...
Leishmaniasis 1.78 7.61e-3 67/77 (87.01%) HLA-DQA1;FOS;IFNGR2;...
Thyroid cancer 1.78 7.26e-3 36/37 (97.3%) GADD45B;CDKN1A;GADD45A;...
Cytokine-cytokine receptor interaction 1.78 7.41e-3 246/295 (83.39%) INHBA;CXCL8;CD40;...
Estrogen signaling pathway 1.77 7.10e-3 119/137 (86.86%) HSPA1A;HSPA6;KRT14;...
Salmonella infection 1.76 9.37e-3 198/249 (79.52%) CXCL8;IL18;AHNAK2;...
Mitophagy 1.75 9.01e-3 56/68 (82.35%) SQSTM1;CITED2;JUN;...
p53 signaling pathway 1.75 9.07e-3 63/73 (86.3%) GADD45B;CDKN1A;SERPINE1;...
MAPK signaling pathway 1.75 9.51e-3 272/294 (92.52%) HSPA1A;HSPA6;GADD45B;...
Longevity regulating pathway 1.74 9.55e-3 90/151 (59.6%) HSPA1A;HSPA6;CRYAB;...
Staphylococcus aureus infection 1.71 1.16e-2 72/95 (75.79%) KRT14;HLA-DQA1;C1QA;...
Valine, leucine and isoleucine degradation -1.68 4.60e-2 42/48 (87.5%) AUH;HIBCH;ACAA1;...
Fatty acid elongation -1.70 4.43e-2 19/27 (70.37%) HACD1;TECR;PPT1;...
Butanoate metabolism -1.71 3.86e-2 23/28 (82.14%) BDH1;GAD1;GAD2;...
Renin-angiotensin system -1.74 3.07e-2 20/23 (86.96%) ACE2;KLK2;ATP6AP2;...
Other glycan degradation -1.78 1.61e-2 13/18 (72.22%) ENGASE;HEXB;MAN2B2;...
Peroxisome -1.80 1.18e-2 72/82 (87.8%) CROT;PEX3;HMGCL;...
Terpenoid backbone biosynthesis -1.81 1.38e-2 18/22 (81.82%) GGPS1;PDSS2;HMGCS1;...
Biosynthesis of unsaturated fatty acids -1.90 1.84e-3 21/27 (77.78%) HACD1;TECR;SCP2;...
Vitamin digestion and absorption -1.93 0.00e+0 17/24 (70.83%) CBLIF;MMACHC;LMBRD1;...
Taurine and hypotaurine metabolism -1.94 0.00e+0 8/11 (72.73%) BAAT;CDO1;GAD1;...
Steroid biosynthesis -2.00 0.00e+0 19/20 (95%) SQLE;SC5D;EBP;...
Propanoate metabolism -2.01 0.00e+0 30/34 (88.24%) SUCLG1;HIBCH;SUCLA2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 3.33uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 3.33uM 24H
SK-N-SH CVCL_0531 Homo sapiens 0.04uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 3.33uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 1.25uM - 40uM 3H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 3.33uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 3.33uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H